|
1
|
Pasquale EB: Eph-ephrin bidirectional
signaling in physiology and disease. Cell. 133:38–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gale NW, Holland SJ, Valenzuela DM,
Flenniken A, Pan L, Ryan TE, Henkemeyer M, Strebhardt K, Hirai H,
Wilkinson DG, et al: Eph receptors and ligands comprise two major
specificity subclasses and are reciprocally compartmentalized
during embryogenesis. Neuron. 17:9–19. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wijeratne DT, Rodger J, Wood FM and Fear
MW: The role of Eph receptors and Ephrins in the skin. Int J
Dermatol. 55:3–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pasquale EB: Eph receptor signalling casts
a wide net on cell behaviour. Nat Rev Mol Cell Biol. 6:462–475.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao Q, Liu W, Cai J, Li M, Gao Y, Lin W
and Li Z: EphB2 promotes cervical cancer progression by inducing
epithelial-mesenchymal transition. Hum Pathol. 45:372–381. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumar SR, Scehnet JS, Ley EJ, Singh J,
Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA,
et al: Preferential induction of EphB4 over EphB2 and its
implication in colorectal cancer progression. Cancer Res.
69:3736–3745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kumar SR, Masood R, Spannuth WA, Singh J,
Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau
L, et al: The receptor tyrosine kinase EphB4 is overexpressed in
ovarian cancer, provides survival signals and predicts poor
outcome. Br J Cancer. 96:1083–1091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hafner C, Becker B, Landthaler M and Vogt
T: Expression profile of Eph receptors and ephrin ligands in human
skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod
Pathol. 19:1369–1377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Herath NI, Doecke J, Spanevello MD,
Leggett BA and Boyd AW: Epigenetic silencing of EphA1 expression in
colorectal cancer is correlated with poor survival. Br J Cancer.
100:1095–1102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Batlle E, Bacani J, Begthel H, Jonkheer S,
Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T,
et al: EphB receptor activity suppresses colorectal cancer
progression. Nature. 435:1126–1130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li JJ, Liu DP, Liu GT and Xie D: EphrinA5
acts as a tumor suppressor in glioma by negative regulation of
epidermal growth factor receptor. Oncogene. 28:1759–1768. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujiwara K, Ghosh S, Liang P, Morien E,
Soma M and Nagase H: Genome-wide screening of aberrant DNA
methylation which associated with gene expression in mouse skin
cancers. Mol Carcinog. 54:178–188. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farshchian M, Nissinen L, Siljamäki E,
Riihilä P, Toriseva M, Kivisaari A, Ala-Aho R, Kallajoki M,
Veräjänkorva E, Honkanen HK, et al: EphB2 promotes progression of
cutaneous squamous cell carcinoma. J Invest Dermatol.
135:1882–1892. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li RX, Chen ZH and Chen ZK: The role of
EPH receptors in cancer-related epithelial-mesenchymal transition.
Chin J Cancer. 33:231–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21 (Suppl 7):vii89–vii92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan W and Chen Z, Wu S, Ge J, Chang S,
Wang X, Chen J and Chen Z: Expression of EphA2 and E-cadherin in
gastric cancer: Correlated with tumor progression and lymphogenous
metastasis. Pathol Oncol Res. 15:473–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saito T, Masuda N, Miyazaki T, Kanoh K,
Suzuki H, Shimura T, Asao T and Kuwano H: Expression of EphA2 and
E-cadherin in colorectal cancer: Correlation with cancer
metastasis. Oncol Rep. 11:605–611. 2004.PubMed/NCBI
|
|
19
|
Schauer MC, Stoecklein NH, Theisen J,
Kropil F, Baldus S, Hoelscher A, Feith M, Bolke E, Matuschek C,
Budach W and Knoefel WT: The simultaneous expression of both ephrin
B3 receptor and E-cadherin in Barrett's adenocarcinoma is
associated with favorable clinical staging. Eur J Med Res.
17:102012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu
Y, Yao Y and Li D: The epithelial to mesenchymal transition (EMT)
and cancer stem cells: implication for treatment resistance in
pancreatic cancer. Mol Cancer. 16:522017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Izumiya M, Kabashima A, Higuchi H,
Igarashi T, Sakai G, Iizuka H, Nakamura S, Adachi M, Hamamoto Y,
Funakoshi S, et al: Chemoresistance is associated with cancer stem
cell-like properties and epithelial-to-mesenchymal transition in
pancreatic cancer cells. Anticancer Res. 32:3847–3853.
2012.PubMed/NCBI
|
|
22
|
Guadamillas MC, Cerezo A and Del Pozo MA:
Overcoming anoikis-pathways to anchorage-independent growth in
cancer. J Cell Sci. 124:3189–3197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Malaguarnera R and Belfiore A: The
emerging role of insulin and insulin-like growth factor signaling
in cancer stem cells. Front Endocrinol (Lausanne). 5:102014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lam S, Wiercinska E, Teunisse AF, Lodder
K, ten Dijke P and Jochemsen AG: Wild-type p53 inhibits
pro-invasive properties of TGF-β3 in breast cancer, in part through
regulation of EPHB2, a new TGF-β target gene. Breast Cancer Res
Treat. 148:7–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harlow E, Williamson NM, Ralston R,
Helfman DM and Adams TE: Molecular cloning and in vitro expression
of a cDNA clone for human cellular tumor antigen p53. Mol Cell
Biol. 5:1601–1610. 1985. View Article : Google Scholar : PubMed/NCBI
|
